Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
隨着製藥巨頭爭相加入肥胖治療市場，羅氏、輝瑞競相尋找下一個奧澤米克
How important it is to have the latest blockbuster in your product portfolio. The pharmaceuticals industry has displayed this over and again in recent years — getting a Covid vaccine to market during the pandemic, and now tackling the obesity epidemic.
在您的產品組合中擁有最新的大片是多麼重要。近年來，製藥行業一遍又一遍地展示了這一點——在疫情期間將Covid疫苗推向市場，現在正在應對肥胖症的流行。
Those with obesity drugs already on the market have proved, through their share price moves in the past months, what it means to have this type of treatment on your roster.
那些已經在市場上出售肥胖藥物的人通過過去幾個月的股價變動證明了將這種治療列入名單意味着什麼。
Novo Nordisk (NYSE:NVO) — with two obesity drugs Ozempic and Wegovy — has jumped by around 300% since it bought Ozempic to the market in 2019, while Eli Lilly (NYSE:LLY) is...
擁有兩種肥胖藥物Ozempic和Wegovy的諾和諾德（紐...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。